ANTI-CD80 ANTIBODY HAVING ADCC ACTIVITY FOR ADCC MEDIATED KILLING OF B CELL LYMPHOMA CELLS ALONE OR IN COMBINATION WITH OTHER THERAPIES

摘要

Methods for treating B cell malignancies, in particular B cell leukemia and lymphoma, using an anti-CD80 antibody alone or in combination with an anti-CD20 antibody or chemotherapy is provided. These methods result in a synergistic anti-tumor response.